Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexofenadine as Adjunct to Standard Therapy in Active Rheumatoid Arthritis
NCT05264025Phase 2Recruiting
- Sponsor
- October 6 University
- Start
- Jun 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fexofenadine in rheumatoid arthritis (RA) (2 arms), sponsored by October 6 University. Primary endpoints: American College of Rheumatology 20% Improvement at 12 weeks, Health Assessment Questionnaire Disability Index at 12 weeks and 1 more. Started Jun 2022; status: recruiting.
02
Drugs
fexofenadine
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05264025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05264025.